Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

Urology
G L AndrioleRoger S Rittmaster

Abstract

To examine the rate of prostate cancer detection in three large randomized placebo-controlled benign prostatic hyperplasia trials of dutasteride. Dutasteride, which lowers serum dihydrotestosterone more than 93% by inhibiting type 1 and type 2 5-alpha-reductase, is effective in the treatment of benign prostatic hyperplasia. However, its effect on the development of prostate cancer is unknown. A total of 4325 men with benign prostatic hyperplasia but without a history, or evidence, of prostate cancer, and a serum prostate-specific antigen level of 1.5 to 10 ng/mL, were randomized to 0.5 mg/day dutasteride or placebo for 24 months. The prostate cancer detection rates for subjects were determined by non-protocol-mandated biopsies, either during the double-blind phase of the study or during the first 3 months of the open-label extension. A follow-up questionnaire was administered to a subset of consenting subjects to ascertain the number, outcomes, and reasons for the prostate biopsies. The cumulative incidence of prostate cancer as an adverse event was significantly lower in the dutasteride versus placebo group at 24 months (1.1% versus 1.9%, P = 0.025) and 27 months (1.2% versus 2.5%, P = 0.002). There were no differences in the ...Continue Reading

References

Mar 1, 1978·The Journal of Clinical Endocrinology and Metabolism·J GellerD de la Vega
Sep 28, 2002·Urology·Claus G RoehrbornUNKNOWN ARIA3001 ARIA3002 and ARIA3003 Study Investigators
Apr 12, 2003·Controlled Clinical Trials·Oliver M BautistaHebert Lepor
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman

❮ Previous
Next ❯

Citations

Nov 6, 2013·Annual Review of Medicine·Goutham VemanaStephen J Freedland
Feb 16, 2010·Asian Journal of Andrology·Louis J Gooren
Dec 15, 2010·Future Oncology·Sarah L Hulin-CurtisJuergen K V Reichardt
Mar 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Barnett S KramerUNKNOWN American Urological Association Practice Guidelines Committee
Nov 8, 2011·The British Journal of General Practice : the Journal of the Royal College of General Practitioners·Brian S BuckleyAziz Sheikh
Nov 10, 2013·PloS One·Alexander B Opoku-AcheampongBrian L Lindshield
Nov 3, 2005·Prostate Cancer and Prostatic Diseases·D C Gould, R S Kirby
Dec 3, 2010·Japanese Journal of Clinical Oncology·Hideyuki AkazaUNKNOWN REDUCE Study Group
Oct 11, 2005·Der Pathologe·D C VerghoJ M Wolff
Jun 18, 2010·Current Urology Reports·Haim Matzkin
Jan 22, 2010·Annals of Surgical Oncology·Ray M Merrill, Bradley D Hunter
Sep 17, 2009·Der Urologe. Ausg. A·R BergesUNKNOWN Society of German Urologists
Jan 18, 2006·Annual Review of Medicine·Eric A Klein
Aug 15, 2006·Current Treatment Options in Oncology·Neil Fleshner, Girish Kulkarni
Nov 13, 2008·International Journal of Impotence Research·C G Roehrborn
Jul 1, 2008·Expert Review of Anticancer Therapy·Mireia MusqueraAlexandre R Zlotta
Jun 29, 2013·Seminars in Oncology·Gurdarshan S SandhuGerald L Andriole
Nov 30, 2012·Urologic Oncology·Kenneth G Nepple, Gerald L Andriole
Apr 23, 2009·Urology·Leonard G GomellaEdouard J Trabulsi
Mar 3, 2009·The Journal of Urology·Barnett S KramerUNKNOWN American Society of Clinical Oncology/American Urological Association
Feb 10, 2009·European Urology·Roger S RittmasterIan M Thompson
Sep 17, 2008·Journal of the American Academy of Dermatology·Nicole E Rogers, Marc R Avram
May 13, 2008·Best Practice & Research. Clinical Endocrinology & Metabolism·Roger S Rittmaster
Feb 19, 2008·The Journal of Urology·Donald J Tindall, Roger S Rittmaster
Jul 24, 2007·The Journal of Urology·Ian M Thompson
Mar 10, 2009·The Prostate·Francesco MontorsiRamiro Castro
Mar 3, 2009·Annals of the New York Academy of Sciences·Yuan-Shan Zhu, Julianne L Imperato-McGinley
Feb 16, 2010·The Urologic Clinics of North America·Andrew J StephensonEric A Klein
Oct 7, 2015·Current Urology Reports·Gillian L Stearns, Jaspreet S Sandhu
Sep 6, 2006·The Journal of Urology·Leonard S MarksGerald L Andriole

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.